FHOD3 是肥厚型心肌病的新致病基因
该研究对3189例无亲缘关系的肥厚型心肌病先证者和2777例无心肌病对照进行FHOD3测序,发现FHOD3候选变异在患者中频率显著更高(2.32% vs 0.65%,p<0.001),并在17个家系中与疾病共分离(LOD 7.92)。FHOD3突变约占肥厚型心肌病1%-2%,表型和心血管事件率与未选择队列相似,建议将FHOD3常规纳入基因检测面板。
要点
- FHOD3候选变异在肥厚型心肌病患者中频率为2.32%,显著高于疾病对照的0.65%。
- FHOD3突变在17个家系中与肥厚型心肌病共分离,LOD评分7.92提示非常强的连锁证据。
- FHOD3应常规纳入肥厚型心肌病基因检测面板。
核心结论
- FHOD3是肥厚型心肌病的新致病基因,约占1%-2%的病例。
- FHOD3突变患者的表型和心血管事件率与未选择队列相似。
研究设计与样本
- 研究对3189例无亲缘关系的肥厚型心肌病先证者和2777例无心肌病对照进行FHOD3大规模平行测序。
- 评估了FHOD3中蛋白改变候选变异的共分离、临床特征和结局。
主要发现
- 在132例先证者中鉴定出94个候选变异。
- FHOD3变异频率在肥厚型心肌病患者中为2.32%(74/3189),显著高于疾病对照的0.65%(18/2777;p<0.001)和gnomAD数据库的0.76%(1049/138606;p<0.001)。
- FHOD3突变在17个家系中与肥厚型心肌病共分离,联合LOD评分为7.92。
- 一半的致病变异聚集在一个小的保守卷曲螺旋结构域(氨基酸622至655);该结构域变异与肥厚型心肌病的比值比分别为21.8(对比疾病对照,95%CI 1.3-37.9;p<0.001)和14.1(对比gnomAD,95%CI 6.9-28.7;p<0.001)。
- 携带FHOD3(可能)致病突变的肥厚型心肌病患者(n=70)诊断年龄在30岁以后(平均46.1±18.7岁),66%为男性;82%有不对称室间隔肥厚(平均18.8±5 mm),14%左心室射血分数<50%,16%有过度小梁化;30岁前事件罕见,随访期间年心血管死亡发生率为1%。
关键数值与推荐
- FHOD3候选变异在肥厚型心肌病患者中频率为2.32%,显著高于疾病对照的0.65%(p<0.001)和gnomAD的0.76%(p<0.001)。
- FHOD3突变在17个家系中与肥厚型心肌病共分离,联合LOD评分为7.92。
- 氨基酸622至655结构域变异的比值比:对比疾病对照为21.8(95%CI 1.3-37.9;p<0.001),对比gnomAD为14.1(95%CI 6.9-28.7;p<0.001)。
- 携带FHOD3(可能)致病突变的患者诊断年龄平均46.1±18.7岁,66%为男性,82%有不对称室间隔肥厚(平均18.8±5 mm),14%左心室射血分数<50%,16%有过度小梁化。
- 30岁前事件罕见,随访期间年心血管死亡发生率为1%。
临床怎么用
- 建议将FHOD3常规纳入肥厚型心肌病的基因检测面板。
- 对检出FHOD3(可能)致病突变的患者,可参考其诊断年龄较晚、事件率较低的表型特征进行管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The genetic cause of hypertrophic cardiomyopathy remains unexplained in a substantial proportion of cases. Formin homology 2 domain containing 3 (FHOD3) may have a role in the pathogenesis of cardiac hypertrophy but has not been implicated in hypertrophic cardiomyopathy. OBJECTIVES: This study sought to investigate the relation between FHOD3 mutations and the development of hypertrophic cardiomyopathy. METHODS: FHOD3 was sequenced by massive parallel sequencing in 3,189 hypertrophic cardiomyopathy unrelated probands and 2,777 patients with no evidence of cardiomyopathy (disease control subjects). The authors evaluated protein-altering candidate variants in FHOD3 for cosegregation, clinical characteristics, and outcomes. RESULTS: The authors identified 94 candidate variants in 132 probands. The variants' frequencies were significantly higher in patients with hypertrophic cardiomyopathy (74 of 3,189 [2.32%]) than in disease control subjects (18 of 2,777 [0.65%]; p < 0.001) or in the gnomAD database (1,049 of 138,606 [0.76%]; p < 0.001). FHOD3 mutations cosegregated with hypertrophic cardiomyopathy in 17 families, with a combined logarithm of the odds score of 7.92, indicative of very strong segregation. One-half of the disease-causing variants were clustered in a small conserved coiled-coil domain (amino acids 622 to 655); odds ratio for hypertrophic cardiomyopathy was 21.8 versus disease control subjects (95% confidence interval: 1.3 to 37.9; p < 0.001) and 14.1 against gnomAD (95% confidence interval: 6.9 to 28.7; p < 0.001). Hypertrophic cardiomyopathy patients carrying (likely) pathogenic mutations in FHOD3 (n = 70) were diagnosed after age 30 years (mean 46.1 ± 18.7 years), and two-thirds (66%) were males. Of the patients, 82% had asymmetric septal hypertrophy (mean 18.8 ± 5 mm); left ventricular ejection fraction <50% was present in 14% and hypertrabeculation in 16%. Events were rare before age 30 years, with an annual cardiovascular death incidence of 1% during follow-up. CONCLUSIONS: FHOD3 is a novel disease gene in hypertrophic cardiomyopathy, accounting for approximately 1% to 2% of cases. The phenotype and the rate of cardiovascular events are similar to those reported in unselected cohorts. The FHOD3 gene should be routinely included in hypertrophic cardiomyopathy genetic testing panels.
引用
- Ochoa JP, Sabater-Molina M, García-Pinilla JM, et al. Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2018. PMID: 30442288. doi:10.1016/j.jacc.2018.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。